VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 700 shares, a decline of 22.2% from the January 31st total of 900 shares. Based on an average daily trading volume, of 12,700 shares, the short-interest ratio is currently 0.1 days.
VanEck Biotech ETF Stock Performance
Shares of NASDAQ:BBH traded up $3.06 during trading on Friday, reaching $165.80. The stock had a trading volume of 10,023 shares, compared to its average volume of 6,011. The business has a fifty day moving average price of $165.71 and a 200-day moving average price of $159.18. VanEck Biotech ETF has a fifty-two week low of $142.51 and a fifty-two week high of $171.04.
VanEck Biotech ETF Announces Dividend
The company also recently disclosed an annual dividend, which was paid on Friday, December 22nd. Stockholders of record on Tuesday, December 19th were given a $0.7127 dividend. The ex-dividend date of this dividend was Monday, December 18th.
Hedge Funds Weigh In On VanEck Biotech ETF
About VanEck Biotech ETF
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Read More
- Five stocks we like better than VanEck Biotech ETF
- How to Find Undervalued Stocks
- MarketBeat Week in Review – 2/26 – 3/1
- What is a Bond Market Holiday? How to Invest and Trade
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- Where to Find Earnings Call Transcripts
- Snowflake Stock Plunges, Don’t be Fooled, Bargain Alert
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.